A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial

American Journal of Obstetrics and Gynecology

Volumn 200, Issue 1, 2009, Pages 80.e1-80.e7

  Duffy, Sean R ^a   Distler, Wolfgang ^e   Howell, Anthony ^b   Cuzick, Jack ^c   Baum, Michael ^d  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

anastrozole; aromatase inhibitor; early breast cancer; gynecologic adverse events; tamoxifen

Indexed keywords

ANASTROZOLE; HORMONE RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLPOSCOPY; CONTROLLED STUDY; CURETTAGE; DILATATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPAREUNIA; ECHOGRAPHY; ENDOMETRIAL DISEASE; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; FEMALE GENITAL TRACT INFECTION; GYNECOLOGIC DISEASE; HUMAN; HYSTERECTOMY; HYSTEROSCOPY; INCIDENCE; LAPAROSCOPY; LEUKORRHEA; MAJOR CLINICAL STUDY; OVARIECTOMY; OVARY CARCINOMA; POLYPECTOMY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRANSVAGINAL ECHOGRAPHY; UTERINE CERVICITIS; UTERINE CERVIX CANCER; UTERUS CANCER; UTERUS DISEASE; VAGINA BLEEDING; VAGINA DISEASE; VULVA DISEASE;

EID: 58049151302     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2008.07.062     Document Type: Article

References (10)

1. Bergman L., Beelen M.L., Gallee M.P., Hollema H., Benraadt J., and van Leeuwen F.E. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer, Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 356 (2000) 881-887
2. Cuzick J., Powles T., Veronesi U., et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361 (2003) 296-300
3. van Leeuwen F.E., Benraadt J., Coebergh J.W., et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343 (1994) 448-452
4. Geisler J., King N., Dowsett M., et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 74 (1996) 1286-1291
5. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
6. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 (2002) 2131-2139
7. The Arimidex Tamoxifen Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9 (2008) 45-53
8. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial efficacy and safety update analyses. Cancer 98 (2003) 1802-1810
9. The ATAC Trialists' Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7 (2006) 633-643
10. Duffy S., Jackson T.L., Lansdown M., et al. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod 21 (2006) 545-553